Experts predict that in-vivo microrobotics is emerging as the next breakthrough in biomedicine. Magnetically controlled, flexible robots can enter the human body through puncture sites or natural orifices to perform tasks beyond conventional surgery, including thrombolysis, tissue sampling, localized drug delivery, and in vivo imaging.
MEDTEX has designated microscopic medical robots alongside AI drug discovery as two core themes of its forum. Allen Wu, Managing Director of Everbright Biofund, cited Swiss company Nanoflex Robotics as an example — a magnetically controlled cardiovascular robot that uses AI to design optimal surgical pathways, enabling remote-controlled clot removal two to four times faster than existing procedures. In 2025, the technology completed the world’s first remote cross-continental animal thrombectomy trial.
Wu noted Taiwan’s strengths in precision manufacturing, MEMS, and clinical capacity position it well to evolve from a contract manufacturer to a global medical technology co-creator.
